Overview
- 6 public-safe observations are available for this inspection.
- 6 structured CFR citations are represented.
- 2 investigators are tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
29 Apr 2026
21 CFR 1271.150(c)(1)(iii)
Ensurane of compliance
Cited by Shelley H Beausoleil, Conor J Mccarron
29 Apr 2026
21 CFR 1271.160(b)(6)
Deviations--evaluation, cause, corrective action
Cited by Shelley H Beausoleil, Conor J Mccarron
29 Apr 2026
21 CFR 1271.195(a)
Adequate control, proper conditions
Cited by Shelley H Beausoleil, Conor J Mccarron
29 Apr 2026
21 CFR 1271.210(a)
Use prior to verification
Cited by Shelley H Beausoleil, Conor J Mccarron
29 Apr 2026
21 CFR 1271.47(a)
Design of procedures to ensure compliance
Cited by Shelley H Beausoleil, Conor J Mccarron
Inspected site
BBBerkeley Biologics LLCRichmond, United States
Inspection team
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 1271.150(c)(1)(iii) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 1271.160(b)(6) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 1271.195(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 1271.210(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 1271.47(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 1271.75(d) | Cited across public-safe Form 483 observations | 1x |
Full 483 report
Get the verbatim text of all 6 observations
The full inspection record, as Atlas holds it, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere